The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-sch nlein Purpura

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    60
  • sponsor
    First Hospital of Jilin University
Updated on 24 January 2021

Summary

The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with Henoch-schnlein purpura.

Description

The investigators designed a single center, open-label, prospective study that routinely administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory parameters to explore its efficacy and to observe changes in immune cell subsets and cytokines.For all patients,rhIL-2(500,000 unit per square meter) infusions seven days;recurrent patients were applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.

Details
Condition Allergic Purpura
Treatment IL-2
Clinical Study IdentifierNCT04387942
SponsorFirst Hospital of Jilin University
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

age <18 years old
meet the EULAR/PRINTO/PRES for the diagnosis of HSP
HIV negative;Negative for HBV and HCV

Exclusion Criteria

heart failure (cardiac function grade III NYHA)
liver insufficiency (upper limit of normal range of transaminase > 2 times)
renal insufficiency (creatinine clearance 30ml/min)
acute or severe infections such as bacteremia and sepsis
malignant tumor
high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the last 1 month
mental disorders or any other chronic illness or substance abuse may interfere with the ability to comply with agreements or provide information
Intestinal ischemia or perforated gastrointestinal bleeding requires surgery
Inability to comply with IL-2 treatment regimen
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note